PubMed HealthSearch

Biomedical subjects

W Tymiński

Publications and source records attributed to W Tymiński.

At least 19 recordsLinked to original sources

[Thrombophilia].

Explore the source record for details and available documents.

Antithrombin III Deficiency

Disturbances of platelet function in patients with multiple myeloma.

Coagulation disturbances in patients with multiple myeloma are presented. Platelet disfunction was especially observed, but only in patients with marked hyperproteinemia and a high level of immunoglobulins in plasma, whereas normal adhesion and aggregation were noticed in 3 out of 17 patients without protein disturbances. Chemotherapy as well as plasma exchange caused not only a decrease of the paraprotein level in plasma, but also a normalization of the failure previously observed in platelet function. Our experiments confirm the opinion that protein M in plasma is responsible for the disturbances observed in multiple myeloma.

Antineoplastic Combined Chemotherapy Protocols

Clinical investigations on long-term activation of fibrinolysis by anabolic steroids.

The influence of anabolic steroids plus phenformin on the course of disease was studied in patients suffering from occlusive vascular diseases. In arteriosclerosis obliterans of the lower limbs the combined therapy led to a higher percentage of improvement than the control group showed. In coronary heart disease there was also a beneficial effect of this treatment. The drugs were found to exert beneficial clinical effects especially in patients with thrombophlebitis migrans and superficial thrombophlebitis. From the results of this study it is concluded that this therapy may be of clinical value in the treatment of patients with occlusive vascular diseases.

Adult

Prevention of experimental gastric ulcers in rats by dial derivatives.

In 111 rats divided into 5 groups, Ipronal (5-allyl-5-(beta-hydroxypropyl)-barbituric acid) protected rats from development of experimental ulceration of the gastric mucosa twice as effectively as diallylbarbituric acid and compound D2H (5-isopropyl-5-(beta-hydroxypropyl)-barbituric acid). Compound D1S (alpha-allophanyl-alpha-allyl-gamma-valerolactone) was devoid of this action.

Animals